- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Erleada
Synonyms :
Class :
Antineoplastic agents & Antiandrogens
Dosage Forms & Strengths
Tablet, Oral:
60 mg
Note: Continuous androgen deprivation therapy is generally used prior to bilateral orchiectomy and with a gonadotropin-releasing hormone analog agonist/antagonist. Do not administer extra tablets to make up for a missed dose, continue the normal dosing schedule.
Metastatic/non-metastatic:
240
mg
Orally
once a day
Tablet
in combination with continuous androgen deprivation therapy
Dose Adjustments
Grade 3 or higher toxicity: Hold the dosing temporarily until symptoms improve to grade 1 or lower and resume the dose with 120 to 180 mg. Cerebrovascular events, grade 3 or 4: discontinue the dosing Dermatologic toxicity: if not managed by oral antihistamines and topical corticosteroids, interrupt or reduce apalutamide dose until symptoms improve Fracture: manage with the use of bone-modifying agents Seizure: discontinue apalutamide dosing permanently Thyroid dysfunction: adjust/ reduce the dose initially, initiate thyroid replacement therapy if indicated
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
It may diminish the effect when combined with irinotecan liposomal by affecting CYP3A4 metabolism
when both drugs are combined, there may be a decreased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
It may diminish the levels when combined with tamsulosin by affecting CYP3A4 metabolism
the concentration of levomenol decreases in the serum when combined with apalutamide
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism.
when both drugs are combined, there may be a decreased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
on interacting with brentuximab vedotin, will decrease its effect by altering the intestinal/hepatic metabolism of CYP3A4 enzyme the drugs containing substrates of CYP3A4 should be avoided during the medication.
when both drugs are combined, there may be a reduced blood level of abemaciclib and result in less effectiveness in treating cancer
when both drugs are combined, there may be an increased metabolism of erlotinib
the effect of apalutamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of apalutamide by affecting hepatic or intestinal enzyme cyp3a4 metabolism
apalutamide decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
apalutamide decreases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
apalutamide decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
apalutamide decreases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be increase in both increase QTc interval
when both drugs are combined, there may be increase in both increase QTc interval
it will decrease the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it decreases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it decreases the effect or level of dronabinol by altering the intestinal or hepatic metabolism
when both drugs are combined, there may be an increased risk of adverse effects
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
It may diminish the levels when combined with tamsulosin by affecting CYP3A4 metabolism
When apalutamide is combined with levobupivacaine, there is a potential for a reduction in the concentration serum of levobupivacaine
when both drugs are combined, there may be a decreased level of serum concentration of etoposide
when both drugs are combined, there may be a decreased levels of serum concentration of vinblastine
when both drugs are combined, there may be an increased metabolism of paclitaxel
increase the excretion and reduce the effects of daunorubicin
the effect of lenvatinib is decreased by apalutamide, thereby increasing elimination.
increase the excretion and reduce the effects of idarubicin
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
may diminish the serum concentration
may enhance the serum concentration of CYP2C8 inhibitors
may increase the serum concentration when it is combined
It may diminish its effectiveness when combined with flotufolastat F-18
Androgen Deprivation Therapy Agents decrease the effect of diagnosis of flotufolastat F18
Androgen Deprivation Therapy Agents decrease the effect of diagnosis of piflufolastat F18
Frequency defined:
>10%:
Hypertension (25%)
Peripheral edema (11%)
Skin rash (25%)
Pruritis (11%)
Weight loss (16%)
Decreased appetite (12%)
Diarrhea (20%)
Nausea (18%)
Falling (16%)
Fatigue (33%)
Bone fracture (9-12%)
1% to 10%
Cardiac failure (2%)
Hypothyroidism (4%)
Dysgeusia (3%0
Muscle spasm (3%)
<1%
Seizure
Postmarketing:
Interstitial pulmonary disease
Stevens-johnson syndrome
Pregnancy consideration: Based on animal reproduction research data, apalutamide may cause fetal harm and potential fetal loss.
Lactation: excretion of apalutamide in breast milk is unknown.
Pregnancy category:
Patient information leaflet
Generic Name: Apalutamide
Pronounced: a-pa-loo-ta-mide
Why do we use apalutamide?
Apalutamide is an antiandrogen class of antineoplastic drug. It is used to treat prostate cancer.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
